EP1037918A4 - Method and composition to enhance the efficacy of a vaccine using chemokines - Google Patents

Method and composition to enhance the efficacy of a vaccine using chemokines

Info

Publication number
EP1037918A4
EP1037918A4 EP98963052A EP98963052A EP1037918A4 EP 1037918 A4 EP1037918 A4 EP 1037918A4 EP 98963052 A EP98963052 A EP 98963052A EP 98963052 A EP98963052 A EP 98963052A EP 1037918 A4 EP1037918 A4 EP 1037918A4
Authority
EP
European Patent Office
Prior art keywords
vaccine
chemokines
efficacy
enhance
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP98963052A
Other languages
German (de)
French (fr)
Other versions
EP1037918A1 (en
EP1037918B1 (en
Inventor
Robert C Gallo
Anthony L Devico
Alfredo Garzino-Demo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland Biotechnology Institute UMBI
Original Assignee
University of Maryland Biotechnology Institute UMBI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Maryland Biotechnology Institute UMBI filed Critical University of Maryland Biotechnology Institute UMBI
Publication of EP1037918A1 publication Critical patent/EP1037918A1/en
Publication of EP1037918A4 publication Critical patent/EP1037918A4/en
Application granted granted Critical
Publication of EP1037918B1 publication Critical patent/EP1037918B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

The present invention relates to a method to enhance the efficacy of a vaccine in a subject treated with the vaccine comprising administering to the subject in combination with the vaccine a one or more chemokines. The present invention also relates to compositions of vaccines containing chemokines.
EP98963052A 1997-12-11 1998-12-11 Compositions to enhance the efficacy of a vaccine using chemokines Expired - Lifetime EP1037918B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6928197P 1997-12-11 1997-12-11
US69281P 1997-12-11
PCT/US1998/026291 WO1999029728A1 (en) 1997-12-11 1998-12-11 Method and composition to enhance the efficacy of a vaccine using chemokines

Publications (3)

Publication Number Publication Date
EP1037918A1 EP1037918A1 (en) 2000-09-27
EP1037918A4 true EP1037918A4 (en) 2004-11-03
EP1037918B1 EP1037918B1 (en) 2009-03-04

Family

ID=22087917

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98963052A Expired - Lifetime EP1037918B1 (en) 1997-12-11 1998-12-11 Compositions to enhance the efficacy of a vaccine using chemokines

Country Status (6)

Country Link
EP (1) EP1037918B1 (en)
AT (1) ATE424217T1 (en)
AU (1) AU1815899A (en)
CA (1) CA2314006A1 (en)
DE (1) DE69840637D1 (en)
WO (1) WO1999029728A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999053960A2 (en) * 1998-04-22 1999-10-28 Chiron Corporation Enhancing immune responses to genetic immunization by using a chemokine
US6919318B1 (en) 1998-04-22 2005-07-19 Chiron Corporation Enhancing immune responses to genetic immunization by using a chemokine
US6562800B1 (en) * 1998-10-30 2003-05-13 University Of Southern California Use of immunopotentiating sequences for inducing immune response
US7708983B2 (en) 1998-12-11 2010-05-04 Alfredo Garzino-Demo Directional induction of immune response by co-administration of antigens with chemokines
US20020086000A1 (en) * 1999-04-15 2002-07-04 Richard Boyd Stimulation of thymus for vaccination development
AU2001253481A1 (en) * 2000-04-21 2001-11-07 Chemocentryx, Inc. Methods and compositions for eleciting an immune response
US7361329B2 (en) 2000-04-21 2008-04-22 Chemocentryx, Inc. Compositions for inducing an immune response
ES2256232T3 (en) * 2000-04-21 2006-07-16 Chemocentryx, Inc. METHODS AND COMPOSITIONS TO CAUSE AN IMMUNE RESPONSE.
WO2002085409A2 (en) * 2001-04-12 2002-10-31 Chemocentryx Methods and compositions for inducing an immune response to an antigen
WO2003035106A1 (en) * 2001-10-24 2003-05-01 Chemocentryx Methods and compositions for inducing an immune response by co-administering a chemokine with an antigen
US7776564B2 (en) 2004-04-30 2010-08-17 Five Prime Therapeutics, Inc. Stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040267A1 (en) * 1995-06-07 1996-12-19 Whitehead Institute For Biomedical Research The regulation of systemic immune responses utilizing cytokines and antigens
WO1996040923A1 (en) * 1995-06-07 1996-12-19 Icos Corporation Macrophage derived chemokine and chemokine analogs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141867A (en) * 1987-02-02 1992-08-25 E. I. Du Pont De Nemours And Company Nucleotide sequence encoding a human immunodeficiency virus antigen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040267A1 (en) * 1995-06-07 1996-12-19 Whitehead Institute For Biomedical Research The regulation of systemic immune responses utilizing cytokines and antigens
WO1996040923A1 (en) * 1995-06-07 1996-12-19 Icos Corporation Macrophage derived chemokine and chemokine analogs

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FURCI LUCINDA ET AL: "Antigen-driven C-C chemokine-mediated HIV-1 suppression by CD4+ T cells from exposed uninfected individuals expressing the wild-type CCR-5 allele", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 186, no. 3, 1997, pages 455 - 460, XP002295797, ISSN: 0022-1007 *
PAL RANAJIT ET AL: "Inhibition of HIV-1 infection by the beta-chemokine MDC", SCIENCE (WASHINGTON D C), vol. 278, no. 5338, 24 October 1997 (1997-10-24), pages 695 - 698, XP002097214, ISSN: 0036-8075 *

Also Published As

Publication number Publication date
CA2314006A1 (en) 1999-06-17
AU1815899A (en) 1999-06-28
EP1037918A1 (en) 2000-09-27
WO1999029728A1 (en) 1999-06-17
ATE424217T1 (en) 2009-03-15
EP1037918B1 (en) 2009-03-04
DE69840637D1 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
BG101132A (en) Pyridoanilated thienyl and furanyl oxazolidinons
MXPA02004770A (en) Therapeutic compositions and methods of use thereof.
PL349028A1 (en) Cancer treatment composition and method using natural plant essential oils
HK1030144A1 (en) Method for treatment of liver tumours and pharmaceutical compositions for use therein.
EP0640097A4 (en) Compositions and methods for vaccination against coronaviruses.
EP1037918A4 (en) Method and composition to enhance the efficacy of a vaccine using chemokines
MXPA02004933A (en) Cosmetic compositions containing chick pea extract and retinoids.
PL316656A1 (en) Free halophantrin base for use in treating marsh-fever and compositions containing same
ZA988941B (en) Conjugated polypeptides for treating Herpes Simples virus, compositions and vaccines containing same and uses thereof for treatment or prevention of Herpes Simplex virus and as diagnostic tool and in diagnostic kit.
IL125797A0 (en) Parapoxviruses which contain foreign dna their preparation and their use in vaccines
CA2418167A1 (en) Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
EP0661061A3 (en) Vaccine composition for eliciting an immune response against N-glycolylated gangliosides and its use for cancer treatment.
EP0694605A3 (en) Cyclic diesters and their use as perfuming ingredients
AU9731198A (en) Histogranin peptide and their analgesic use
IL140588A0 (en) Therapeutic composition based on flavonoids intended to be used in the treatment of tumours by cytotoxic agents
BG100248A (en) Squalene synthetase inhibitors
EP0612840A3 (en) Cyclic compounds and their use as perfuming ingredients.
EP1303520A4 (en) Therapeutic compounds and methods
AU2636602A (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
BR0111785A (en) Compositions and methods for treating candidiasis
AU9588398A (en) Vaccine compositions and methods of enhancing vaccine efficacy
NZ514027A (en) Cloning and expression of haemophilus somnus transferrin-binding proteins
DK0980379T3 (en) Chimeric oligonucleotides and their use
IL143644A0 (en) Composition and formulations and their use as nociceptic, anti-anxiolytic and anabolic agents
IL148351A0 (en) Therapeutic immune condition compositions and methods

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000710

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20040922

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 39/21 B

Ipc: 7A 61K 48/00 B

Ipc: 7A 61K 38/19 B

Ipc: 7C 07K 14/52 B

Ipc: 7A 61K 39/39 A

17Q First examination report despatched

Effective date: 20060825

RTI1 Title (correction)

Free format text: COMPOSITIONS TO ENHANCE THE EFFICACY OF A VACCINE USING CHEMOKINES

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69840637

Country of ref document: DE

Date of ref document: 20090416

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090304

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090304

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090604

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090304

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090304

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090818

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090615

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090304

26N No opposition filed

Effective date: 20091207

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100701

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20091211

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20100831

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091231

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091211

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090605

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091231

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100701

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091211

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090304

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091211

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090304